The infant formula ban grabs the clearest regulatory headline, but there is a parallel body of research on guar gum's effects in adults that is worth knowing about, particularly for anyone with inflammatory bowel disease or a sensitive gut.
Two studies from a research group at the Crohn's & Colitis Foundation explored what happens when mice are fed a diet containing refined guar gum. The results were not reassuring for people with gut conditions.
In the first set of experiments, mice fed guar gum showed increased susceptibility to colitis when inflammation was triggered. Compared to control animals, the guar gum group experienced more rectal bleeding, diarrhea, and splenomegaly. Systemic and colonic markers of inflammation were higher. Crucially, when the gut microbiota was depleted with broad-spectrum antibiotics, the susceptibility to colitis reversed, pointing to microbiome alterations as the mechanism rather than guar gum acting directly on gut tissue.
A follow-up study found that the microbiome changes guar gum induced were specific. Guar gum-fed mice showed elevated branched-chain amino acids, reduced butyrate levels, altered gut microbiota community structure, and a substantial decrease in colonic IL-18 production. IL-18 is a cytokine that plays an important role in maintaining the intestinal epithelial barrier. When the researchers supplemented with recombinant IL-18, the increased colitis susceptibility in guar gum-fed mice was alleviated, clarifying the mechanism.
Important Context
These are animal studies, and mouse models of colitis do not translate perfectly to human disease. The research does not demonstrate that guar gum causes IBD in humans, and the dietary concentrations used in some studies are higher than typical human exposure from food.
What the research does suggest is that for people already living with IBD or other gut conditions, guar gum may not be a neutral bystander. It appears to interact with the gut microbiome in ways that could worsen an already inflamed intestinal environment. For people in remission who are trying to minimize dietary triggers, this is a signal worth taking seriously, even in the absence of human clinical trial data.